A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Azithromycin as Prophylaxis Against the Development of Mycobacterium Avium Complex Disease in HIV-Infected People
Sponsor: Pfizer
Listed as NCT00002309, this NA trial focuses on HIV Infections and Mycobacterium Avium-Intracellulare Infection and remains completed. Sponsored by Pfizer, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Fort Bragg, United States
- • Lackland Air Force Base, United States
- • San Diego, United States